

Comparison of the Initial Treatment Results of N-myc Positive and N-myc Negative Neuroblastoma Patients

Arzania MT¹, Mahmoodi Nesheli H^{*2}, Alavi S¹, Shamsian BS¹, Maasomnia Samakosh A¹, Eghbali A¹, Ahmadi M³, Jadali F⁴, Bijani A²

1- Department of Pediatrics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2- Non-communicable pediatric disease research center, Babol University of Medical Sciences, Babol, Iran.

3- Department of Pathology, Children's Hospital Medical Center, Tehran University of Medical Sciences, Tehran, Iran

4- Department of Pathology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

***Corresponding Author:** Mahmoodi Nesheli H, Email: mahmoodi86@yahoo.com

Submitted: 12-02-2010, Accepted: 10-08-2010

Abstract

Background: Neuroblastoma is the most common extra cranial malignant solid tumor of childhood. Various molecular and cytogenetic factors have been implicated in the pathogenesis of neuroblastoma, some of which have proven useful in predicting clinical behavior. Over expression of the oncogen N-myc, is an important indicator of prognosis.

Materials and Methods: Our study was performed from 2004 to 2008 in Mofid Children's Hospital in Tehran, Iran. In our case control study patients who were diagnosed as neuroblastoma were enrolled. They were checked for N-myc by fluorescence in situ hybridization (FISH) method in tumor tissue. Initially all patients were treated with conventional chemotherapy then were accessed to define their responses.

Results: In our study 18 patients were diagnosed as neuroblastoma. Twelve of them were female and six of them were male. They were 6 month to 6 years old. Eight patients were N-myc positive (case) and ten patients were N-myc negative (control). None of N-myc positive patients responded to conventional chemotherapy, but eight N-myc negative patients responded to conventional chemotherapy. N-myc in neuroblastoma had a significant correlation with the prognosis (PV =0.028).

Conclusion: We suggest conventional chemotherapy for N-myc negative patients and intensive chemotherapy for N-myc positive patients to obtain the best results.

Key words: Neuroblastoma, solid tumor, cancer, childhood, genetics

Introduction

Neuroblastoma is the most common extra cranial malignant solid tumor of childhood ¹. The median age at diagnosis is 17.3 months and 40 percent of patients are diagnosed before one year of age ². Various molecular and cytogenetic factors have been implicated in the pathogenesis of neuroblastoma ³⁻⁴. N-myc amplification, deletions of 1p chromosome and deletions of 11q chromosome have an important role in choosing treatment protocol ⁵⁻⁷. N-myc amplification is found in approximately 25 percent of neuroblastomas ⁸⁻¹⁰. Patients with diploid tumors characterized by an amplified N-myc locus represent a particularly unfavorable risk group that may benefit from innovative new therapies ^{4,11}. Members of the myc gene family, including N-myc, myc, and L-myc, have been found amplified and expressed at high levels

in various human cancers ¹²⁻¹⁴. The complexities in transcription of N-myc expand the means by which expression of the gene might be controlled ¹⁵. Sequences of the short arm of chromosome 2 containing the N-myc oncogen at 2p23-p24 are often involved in DNA amplification ¹⁶. A high expression of N-myc on mRNA level is correlated to the N-myc gene-amplification ¹⁷. Neuroblastoma cells in bone marrow are detected by Southern Blot and in situ hybridization using a N-myc DNA probe ¹⁸⁻¹⁹. N-myc amplified Neuroblastoma cell lines do not express CD44 at all or express a nonfunctional receptor, whereas nonamplified cells constitutively express an active receptor ²⁰. Fluorescence in situ hybridization (FISH), Southern Blot analysis and Light Cycler monoplex polymerase chain reaction (PCR) are used to assess N-myc ²¹. Monoclonal antibodies

have been developed against the putative N-myc gene product made in *Escherichia coli* as a fusion protein. Treatment of patients with high risk neuroblastoma (N-myc+) with new protocol have been associated with good results²²⁻²³. The effect of gamma interferon treatment and distribution of the N-myc protein in the nucleus have also been studied²⁴. There is an antisense peptide nucleic acid (PNA) targeted against a unique sequence in the terminus of the 5'-UTR of N-myc, designed for selective inhibition of N-myc in neuroblastoma cells²⁵. We aimed to evaluate the initial treatment results of N-myc positive and N-myc negative neuroblastoma patients undergoing surgery followed by multi-agent moderate intensity chemotherapy. We studied this phenomenon using a case control design.

Materials and Methods

Our study was done from 2004 to 2008 in Mofid Children's Hospital in Tehran, Iran. Eighteen patients who had been diagnosed with partially resectable localized neuroblastoma were enrolled. All patients were diagnosed as neuroblastoma based on clinical findings, imaging studies and laboratory data. They initially underwent surgery for resection of tumor as soon as possible, and to confirm the diagnosis and make a staging state. The surgical treatment was followed by multi-agent moderate intensity chemotherapy. We checked tumor tissue for N-myc using FISH method. Initially patients received six courses of oncovin, carboplatin, etoposide and cyclophosphamide (OPEC) without consideration of N-myc amplification. They were assessed by computerized tomography (CT) scanning after tumor resection and right before starting the chemotherapy. After every three months of chemotherapy and at the end of six courses of chemotherapy patients were assessed again by CT scan to detect the degree of tumor shrinkage. We collected 24 hr urine to measure homovanilic acid and Vanilic Mandelic acid. We also measured serum

ferritin and serum ceruloplasmin levels. Bone marrow aspiration, bone marrow biopsy and bone scan were performed to rule out bone and bone marrow metastasis at the start and at the end of therapy. Finally using these assessments we defined if the tumor has responded to chemotherapy or not. Statistical comparison was performed using Fisher exact test.

Results

In our study 18 patients were diagnosed as partially resectable localized tumors. They were 6 months to 6 years old and twelve patients were females and six were males. Microscopic study of tissue samples was compatible with neuroblastoma. All of patients were stage II and stage III. They were divided into two groups; group 1 (case) were N-myc positive patients and group 2 (control) were N-myc negative patients. The mean age in group 1 and in group 2 were 1.37 and 2.39 respectively. There were eight patients (44 percent) N-myc positive and ten patients (55 percent) N-myc negative. Bone marrow aspiration, bone marrow biopsy and bone scan showed no metastasis at the start and the end of therapy. CT scan studies at the end of chemotherapy in group 1 did not show complete remission but in group 2 eight patients (80 percent) showed complete remission. That means all ten N-myc positive patients developed recurrent disease after surgery followed by multi-agent moderate intensity chemotherapy. N-myc in neuroblastoma had a significant correlation with the prognosis ($P=0.028$).

Discussion

The observed overall N-myc amplification prevalence of 44% in our study is higher than other reports of 20 to 25% overall prevalence²⁶. In our study none of eight N-myc positive patients responded to conventional chemotherapy after partial surgical resection of tumor which differs from the results of other centers²⁷⁻²⁸. But eight

Table 1: Chemotherapy inducing remission in neuroblastoma patients based on their N-myc status\

| | Number | Treatment | Resistance | PV |
|------------------|--------|-----------|------------|-------|
| Case (N-myc+) | 8 | OPEC | 8 | 0.028 |
| Control (N-myc-) | 10 | OPEC | 2 | 0.028 |

of ten N-myc negative patients (80 percent) responded to conventional chemotherapy which is comparable to the results from other centers^{10, 29-30}. Although few patients were referred to our medical center thorough a four years period, the correlation of n-myc with chemotherapy inducing tumor shrinkage was significant. N-myc positive patients were very poor and n-myc negative patients were very good responders to multi-agent moderate intensity chemotherapy. It seems that all neuroblastoma tumor tissues should be checked for N-myc using FISH method after surgery and before starting the chemotherapy. Also we suggest continuing conventional chemotherapy for N-myc negative patients and intensive chemotherapy for N-myc positive patients in the first day of treatment to obtain the best results. N-myc positive patients should be considered for autologous stem cell transplantation after myeloablative chemotherapy and Meta Iodo benzyl guanine in 32MIBG avid patients.

Conclusion

We suggest conventional chemotherapy for N-myc negative patients and intensive chemotherapy for N-myc positive patients to obtain the best results.

References

- Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL. Infant cancer in the US: histology-specific incidence and trends, 1973 to 1992. *Journal of pediatric hematology/oncology*. 1997;19(5):428.
- Brodeur G, Maris J. Neuroblastoma in principles and practice of pediatric oncology. Pizzo PA, Poplack DG, (eds) Houston Lippincott-Williams Wilkins Publishers. 2006:939-40.
- Schwab M. MYCN in neuronal tumours. *Cancer letters*. 2004;204(2):179-87.
- Dokhi M, Ohtaki M, Hiyama E. A cure Weibull gamma-frailty survival model and its application to exploring the prognosis factors of neuroblastoma. *Hiroshima journal of medical sciences*. 2009;58(1):25.
- Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. *New England Journal of Medicine*. 2005;353(21):2243-53.
- Stallings R, Howard J, Dunlop A, Mullarkey M, McDermott M, Breatnach F, et al. Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma? *Cancer genetics and cytogenetics*. 2003;140(2):133-7.
- Breen C, O'Meara A, McDermott M, Mullarkey M, Stallings R. Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization. *Cancer genetics and cytogenetics*. 2000;120(1):44-9.
- Maris JM, Matthay KK. Molecular biology of neuroblastoma. *Journal of clinical oncology*. 1999;17(7):2264.
- Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. *New England Journal of Medicine*. 1985;313(18):1111-6.
- Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EI, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D (S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. *Journal of clinical oncology*. 1998;16(6):2007.
- Bowman LC, Castleberry RP, Cantor A, Joshi V, Cohn SL, Smith EI, et al. Genetic Staging of Unresectable or Metastatic Neuroblastoma in Infants: a Pediatric Oncology Group Study. *Journal of the National Cancer Institute*. 1997;89(5):373.
- Breit S, Schwab M. Suppression of MYC by high expression of NMYC in human neuroblastoma cells. *Journal of Neuroscience Research*. 1989;24(1):21-8.
- Giannini G, Di Marcotullio L, Ristori E, Zani M, Crescenzi M, Scarpa S, et al. HMGI (Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness. *Cancer research*. 1999;59(10):2484-92.
- Borrello M, Bongarzone I, Plerotti M, Luksch R, Gasparini M, Collini P, et al. trk and ret proto-oncogene expression in human neuroblastoma specimens: High frequency of trk expression in non-advanced stages. *International journal of cancer*. 1993;54(4):540-5.
- Stanton LW, Bishop JM. Alternative processing of RNA transcribed from NMYC. *Molecular and cellular biology*. 1987;7(12):4266-72.
- Winqvist R, Mäkelä T, Seppänen P, Jänne O, Alhonen-Hongisto L, Jänne J, et al. Human ornithine decarboxylase sequences map to chromosome regions 2pter→ p23 and 7cen→ qter but are not coamplified with the NMYC oncogene. *Cytogenetic and Genome Research*. 1986;42(3):133-40.
- Kabisch H, Heinsohn S, Milde K, Löning T, Bartl

- S, Erttmann R, et al. Detection of neuroblastoma cells in bone marrow by Southern blot and in situ hybridization using a NMYC DNA probe. *Monatsschrift Kinderheilkunde: Organ der Deutschen Gesellschaft für Kinderheilkunde*. 1987;135(4):210-3.
18. Garson J, Van den Berghe J, Kemshead J. High-resolution in situ hybridization technique using biotinylated NMYC oncogene probe reveals periodic structure of HSRs in human neuroblastoma. *Cytogenetics and cell genetics*. 1987;45(1):10-5.
 19. Gross N, Balmas K, Brognara CB. Role of CD44H carbohydrate structure in neuroblastoma adhesive properties. *Medical and Pediatric Oncology*. 2001;36(1):139-41.
 20. Gross N, Balmas K, Brognara CB. Absence of functional CD44 hyaluronan receptor on human NMYC-amplified neuroblastoma cells. *Cancer research*. 1997;57(7):1387-93.
 21. Layfield LJ, Willmore-Payne C, Shimada H, Holden JA. Assessment of NMYC amplification: a comparison of FISH, quantitative PCR monoplexing and traditional blotting methods used with formalin-fixed, paraffin-embedded neuroblastomas. *Analytical and quantitative cytology and histology/ the International Academy of Cytology [and] American Society of Cytology*. 2005;27(1):5-14.
 22. Ikegaki N, Bukovsky J, Kennett RH. Identification and characterization of the NMYC gene product in human neuroblastoma cells by monoclonal antibodies with defined specificities. *Proceedings of the National Academy of Sciences*. 1986;83(16):5929-33.
 23. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. *Journal of clinical oncology*. 2009;27(7):1007-13.
 24. Triche TJ. Neuroblastoma and other childhood neural tumors: a review. *Fetal & Pediatric Pathology*. 1990;10(1-2):175-93.
 25. Vita M, Henriksson M, editors. *The Myc oncoproteins as a therapeutic target for human cancer 2006*: Elsevier.
 26. Bown N. Neuroblastoma tumour genetics: clinical and biological aspects. *J Clin Pathol*. 2001 Dec;54(12):897-910.
 27. Castel V, Canete A, Navarro S, García-Miguel P, Melero C, Acha T, et al. Outcome of high-risk neuroblastoma using a dose intensity approach: Improvement in initial but not in long-term results. *Medical and Pediatric Oncology*. 2001;37(6):537-42.
 28. Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, et al. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study. *Journal of clinical oncology*. 2004;22(20):4119-26.
 29. Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. *Journal of clinical oncology*. 2000;18(3):477-86.
 30. Alvarado CS, London WB, Look AT, Brodeur GM, Altmiller DH, Thorner PS, et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. *Journal of pediatric hematology/oncology*. 2000;22(3):197-205.